Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses

MUNICH, UNITED STATES - Mar 8, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response.

“Definiens leads the industry in characterizing and discovering biomarker signatures for immuno-oncology, and with the Immunoprofiling Panel we’re providing an even simpler and more accurate way for researchers to screen samples for an immune response,” said Merrilyn Datta, Chief Commercial Officer. “Researchers simply choose from a list of biomarkers, and we immediately run their samples through our solution to provide them with the immunoprofile data they need.”

While genetic and expression assays can be useful in determining cancer drivers, they cannot effectively characterize the immune system response in the tumor. Functional populations of immune cells are located in different areas of a tumor, which varies between cancer types, suggesting that different immune cell populations may play different roles. Thus, understanding not only the presence of key markers, but also their location within the tumor is critical for true measurement of immune response.

“Definiens provides the only technology to accurately quantitate the immune cell subpopulations and markers in spatial context, including single marker measurements and relationships of defined cell types,” said Thomas Heydler, CEO. “Further simplifying this process with the Immunoprofiling Panel service gives researchers the ability to quickly screen samples for an immune response and generate the critical immunoprofile data they need for effective pipeline decision-making in immuno-oncology.”

The Immunoprofiling Panel currently includes biomarkers PD-1, PD-L1, OX40, CTLA-4, CD3, CD4, CD8, CD20, CD68, CD163 and FoxP3.

For more information about Definiens’ technology, visit www.definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.